Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy

Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.

BACKGROUND AND OBJECTIVES Circulating autoantibodies against the M-type phospholipase A(2) receptor (anti-PLA(2)R) were recently identified in the majority of patients in the United States with idiopathic membranous nephropathy (iMN). The objectives of this study were to assess the prevalence of anti-PLA(2)R in a separate, European cohort of iMN patients and to correlate the presence of anti-PL...

Idiopathic membranous nephropathy and anti-phospholipase A2 receptor antibodies.

current concepts on anti-phospholipase a2 receptor antibody in idiopathic membranous nephropathy.

letter to the editor

Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues.

The discovery of theM-type phospholipase A2 receptor (PLA2R) as a major antigen in idiopathic membranous nephropathy (iMN) was a breakthrough and established iMN as an autoimmune disease.1 Subsequent studies confirmed that antibodies against PLA2R were present in approximately 70% of incident iMN patients (reviewed by Hofstra and Wetzels2). The potential role ofmeasuring PLA2R antibodies for cl...

Anti-phospholipase A2 receptor antibody in membranous nephropathy.

The M-type phospholipase A2 receptor (PLA2R) is a target autoantigen in adult idiopathic membranous nephropathy (MN), but the prevalence of autoantibodies against PLA2R is unknown among Chinese patients with MN. Here, we measured anti-PLA2R antibody in the serum of 60 patients with idiopathic MN, 20 with lupus-associated MN, 16 with hepatitis B (HBV)-associated MN, and 10 with tumor-associated ...